{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T19:40:27Z","timestamp":1740339627496,"version":"3.37.3"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.clinthera.2024.12.002","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T20:14:17Z","timestamp":1735676057000},"page":"204-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment Persistence Among Anti-Tumor Necrosis Factor\u2013experienced Patients With Ulcerative Colitis Switching to a Biologic With a Different Mode of Action or Cycling to Another Anti\u2013Tumor Necrosis Factor Agent"],"prefix":"10.1016","volume":"47","author":[{"given":"Maryia","family":"Zhdanava","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabree","family":"Burbage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Porpong","family":"Boonmak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumesh","family":"Kachroo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditi","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bridget","family":"Godwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic","family":"Pilon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.12.002_bib0001","unstructured":"Crohn's & Colitis Foundation of America. Inflammatory bowel diseases. http:\/\/www.crohnscolitisfoundation.org\/assets\/pdfs\/updatedibdfactbook.pdf. Accessed May 15, 2018."},{"key":"10.1016\/j.clinthera.2024.12.002_bib0002","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s10620-012-2371-5","article-title":"Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population","volume":"58","author":"Kappelman","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0003","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1053\/j.gastro.2023.07.003","article-title":"Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States","volume":"165","author":"Lewis","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0004","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.mayocp.2019.01.018","article-title":"Ulcerative colitis","volume":"94","author":"Feuerstein","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0005","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0006","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/gastro\/gou070","article-title":"Biological therapy for ulcerative colitis","volume":"3","author":"Arora","year":"2015","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0007","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0008","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/MEG.0000000000001730","article-title":"Small molecule drugs in the treatment of inflammatory bowel diseases: which one, when and why? - a systematic review","volume":"32","author":"Lucaciu","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0009","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3389\/fmed.2020.00517","article-title":"Personalizing treatment in IBD: hype or reality in 2020? Can we predict response to anti-TNF?","volume":"7","author":"Atreya","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0010","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to anti-TNFs: definition, epidemiology, and management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0011","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3390\/jcm10040853","article-title":"Predictors and early markers of response to biological therapies in inflammatory bowel diseases","volume":"10","author":"Privitera","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0012","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1097\/MIB.0000000000001145","article-title":"Incidence of and predictors for early discontinuation of biological therapies in veteran patients with inflammatory bowel disease","volume":"23","author":"Feagins","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0013","first-page":"495","article-title":"Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review","volume":"44","author":"Khan","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0014","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/ibd\/izz001","article-title":"Real-world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy","volume":"25","author":"Chen","year":"2019","journal-title":"Inflamm Bowel Dis"},{"year":"2022","series-title":"STELARA\u00ae (ustekinumab) [prescribing information]","key":"10.1016\/j.clinthera.2024.12.002_bib0015"},{"year":"2022","series-title":"ENTYVIO\u00ae (vedolizumab) [prescribing information]","key":"10.1016\/j.clinthera.2024.12.002_bib0016"},{"year":"2021","series-title":"REMICADE\u00ae (infliximab) [prescribing information]","key":"10.1016\/j.clinthera.2024.12.002_bib0017"},{"year":"2021","series-title":"HUMIRA\u00ae (adalimumab) [prescribing information]","key":"10.1016\/j.clinthera.2024.12.002_bib0018"},{"year":"2019","series-title":"SIMPONI\u00ae (golimumab) [prescribing information]","key":"10.1016\/j.clinthera.2024.12.002_bib0019"},{"year":"2009","series-title":"STELARA\u00ae (ustekinumab) [package insert]","key":"10.1016\/j.clinthera.2024.12.002_bib0020"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0021","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/03007995.2023.2178148","article-title":"Treatment persistence among bio-na\u00efve patients with Crohn's disease initiated on ustekinumab or adalimumab","volume":"39","author":"Zhdanava","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0022","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/oxfordjournals.aje.a009735","article-title":"Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study","volume":"149","author":"Bernstein","year":"1999","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0023","first-page":"2133","article-title":"Association between the use of antibiotics and new diagnoses of Crohn's disease and ulcerative colitis","volume":"106","author":"Shaw","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0024","first-page":"90","article-title":"Inconsistencies in the days supply values reported in pharmacy claims databases for biologics with long maintenance intervals","volume":"29","author":"Xu","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"year":"2014","series-title":"ENTYVIO (vedolizumab) [prescribing information]","key":"10.1016\/j.clinthera.2024.12.002_bib0025"},{"year":"2021","series-title":"REMICADE (infliximab) [prescribing information]","key":"10.1016\/j.clinthera.2024.12.002_bib0026"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0027","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn's disease in adults [published correction appears in Am J Gastroenterol. 2018;113:1101]","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0028","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research","volume":"38","author":"Austin","year":"2009","journal-title":"Commun Stat Simul Comput"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0029","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.14309\/01.ajg.0000996076.87488.b0","article-title":"Real-world treatment persistence among advanced therapy-experienced patients with ulcerative colitis initiated on ustekinumab or adalimumab","volume":"118","author":"Zhdanava","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0030","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1080\/03007995.2022.2071041","article-title":"Treatment persistence and maintenance dose titration among ulcerative colitis patients on biologics: a pooled study of three United States claim databases","volume":"38","author":"Sah","year":"2022","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0031","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.clinthera.2023.06.013","article-title":"Persistence among patients with Crohn disease previously treated with an anti-tumor necrosis factor inhibitor and switching or cycling to another biologic agent","volume":"45","author":"Zhdanava","year":"2023","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0032","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.gastro.2017.07.031","article-title":"American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases","volume":"153","author":"Vande Casteele","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0033","first-page":"656","article-title":"Etiology and management of lack or loss of response to anti-tumor necrosis factor therapy in patients with inflammatory bowel disease","volume":"15","author":"Fine","year":"2019","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0034","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/apt.12869","article-title":"Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease","volume":"40","author":"Mazor","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0035","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/ajg.2014.146","article-title":"Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases","volume":"109","author":"Roblin","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0036","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/ecco-jcc\/jjab058","article-title":"Vedolizumab and anti-tumour necrosis factor \u03b1 real-world outcomes in biologic-na\u00efve inflammatory bowel disease patients: results from the EVOLVE study","volume":"15","author":"Bressler","year":"2021","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0037","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/ajg.2011.60","article-title":"Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review","volume":"106","author":"Billioud","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0038","first-page":"760","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review","volume":"104","author":"Gisbert","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0039","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175099","article-title":"Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States","volume":"12","author":"Patel","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0040","article-title":"Indicators of suboptimal treatment and associated healthcare costs among patients with Crohn's disease initiated on biologic or conventional agents","volume":"4","author":"Pilon","year":"2022","journal-title":"Crohn's Colitis"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0041","doi-asserted-by":"crossref","first-page":"AB91","DOI":"10.1016\/j.jaad.2022.06.399","article-title":"34304 Persistence and adherence to ixekizumab treatment in patients with moderate-to-severe psoriasis before and during COVID-19 pandemic: results from the Canadian Patient Support Program","volume":"87","author":"Gulliver","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clinthera.2024.12.002_bib0042","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1007\/s13555-023-00967-3","article-title":"Apremilast adherence and persistence in patients with psoriasis and psoriatic arthritis in the telehealth setting versus the in-person setting during the COVID-19 pandemic","volume":"13","author":"Das","year":"2023","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824003758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824003758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T19:10:24Z","timestamp":1740337824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824003758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0149291824003758"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.12.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Persistence Among Anti-Tumor Necrosis Factor\u2013experienced Patients With Ulcerative Colitis Switching to a Biologic With a Different Mode of Action or Cycling to Another Anti\u2013Tumor Necrosis Factor Agent","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}